Patents by Inventor Madeleine SCHARF
Madeleine SCHARF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11835519Abstract: A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.Type: GrantFiled: December 8, 2020Date of Patent: December 5, 2023Assignees: EUROIMMUN Medizinische Labordiagnostika AG, Mayo Foundation for Medical Education and ResearchInventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Stefanie Hahn, Christiane Radzimski, Mandy Unger, Andrew McKeon, Sean Pittock, Thomas Kryzer, Vanda Lennon, Josephe Honorat
-
Publication number: 20220317121Abstract: A method can be used for detecting, in a sample, an autoantibody binding to a polypeptide having the sequence SEQ ID NO: 1, SEQ ID NO: 11 or SEQ ID NO: 24. A carrier containing said polypeptide and an autoantibody binding to said polypeptide are useful. The autoantibody may be used for the diagnosis of a disease, and a method can be used for isolating an autoantibody binding to said polypeptide. The polypeptide and a kit containing said polypeptide are useful, and can be used for the manufacture of a kit or medical device. A method involves contacting a medical or diagnostic device containing said polypeptide with a buffered solution containing an antibody binding specifically to said polypeptide. A sample containing said autoantibody as a positive control and a diluted sample containing said autoantibody are useful.Type: ApplicationFiled: March 23, 2022Publication date: October 6, 2022Applicant: EUROIMMUN Medizinische Labordiagnostika AGInventors: Zitao ZENG, Lars Komorowski, Ramona Miske, Madeleine Scharf, Yvonne Denno, Christiane Radzimski, Nadine Rochow, Stefanie Brakopp
-
Patent number: 11371991Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.Type: GrantFiled: June 17, 2020Date of Patent: June 28, 2022Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Winfried Stoecker, Lars Komorowski, Ramona Miske, Yvonne Denno, Madeleine Scharf, Christian Probst, Iswariya Venkataraman, Stephanie Kade
-
Patent number: 11112407Abstract: The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.Type: GrantFiled: June 3, 2015Date of Patent: September 7, 2021Assignee: EUROIMMUN Medizinische Labordiagnostika AGInventors: Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Fedor Heidenreich, Ralf Gieß
-
Publication number: 20210181196Abstract: A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.Type: ApplicationFiled: December 8, 2020Publication date: June 17, 2021Applicants: EUROIMMUN Medizinische Labordiagnostika AG, Mayo Foundation for Medical Education and ResearchInventors: Ramona MISKE, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Stefanie Hahn, Christiane Radzimski, Mandy Unger, Andrew McKeon, Sean Pittock, Thomas Kryzer, Vanda Lennon, Josephe Honorat
-
Patent number: 10989712Abstract: A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.Type: GrantFiled: September 25, 2019Date of Patent: April 27, 2021Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Madeleine Scharf, Lars Komorowski, Ramona Miske, Stefanie Hahn, Yvonne Denno, Christian Probst, Farid Benkhadra
-
Publication number: 20200309775Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.Type: ApplicationFiled: June 17, 2020Publication date: October 1, 2020Inventors: Winfried STOECKER, Lars KOMOROWSKI, Ramona MISKE, Yvonne DENNO, Madeleine SCHARF, Christian PROBST, Iswariya VENKATARAMAN, Stephanie KADE
-
Patent number: 10725035Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.Type: GrantFiled: June 15, 2018Date of Patent: July 28, 2020Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Winfried Stoecker, Lars Komorowski, Ramona Miske, Yvonne Denno, Madeleine Scharf, Christian Probst, Iswariya Venkataraman, Stephanie Kade
-
Publication number: 20200096506Abstract: A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.Type: ApplicationFiled: September 25, 2019Publication date: March 26, 2020Applicant: EUROIMMUN Medizinische Labordiagnostika AGInventors: Madeleine SCHARF, Lars Komorowski, Ramona Miske, Stefanie Hahn, Yvonne Denno, Christian Probst, Farid Benkhadra
-
Patent number: 10466239Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient and also antibody binding to RGS8, a method for diagnosing a disease comprising the step detecting in a sample from a patient the level or activity of RGS8, a polypeptide comprising RGS8 or a variant thereof, a use of set polypeptide for the diagnosis of a disease, an antibody binding to RGS8, a use of the antibody for the diagnosis of the disease, a method for isolating an autoantibody binding to RGS8, a pharmaceutical composition or medical device comprising the polypeptide according to the present invention, a kit for the diagnosis of a disease comprising the polypeptide or the medical device according to the present invention and a use of the polypeptide, the antibody or the antibody for the manufacture of a kit or medical device.Type: GrantFiled: April 16, 2018Date of Patent: November 5, 2019Assignee: EUROIMMUN MEDIZINISHE LABORDIAGNOSTIKA AGInventors: Winfried Stoecker, Lars Komorowski, Ramona Miske, Yvonne Denno, Madeleine Scharf, Christian Probst
-
Publication number: 20180364228Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.Type: ApplicationFiled: June 15, 2018Publication date: December 20, 2018Inventors: Winfried STOECKER, Lars KOMOROWSKI, Ramona MISKE, Yvonne DENNO, Madeleine SCHARF, Christian PROBST, Iswariya VENKATARAMAN, Stephanie KADE
-
Patent number: 10138285Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.Type: GrantFiled: June 3, 2016Date of Patent: November 27, 2018Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Winfried Stoecker, Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Stefanie Hahn, Stephanie Kade, George Trendelenburg
-
Patent number: 10112982Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.Type: GrantFiled: March 23, 2016Date of Patent: October 30, 2018Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stöcker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
-
Publication number: 20180306787Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient and also antibody binding to RGS8, a method for diagnosing a disease comprising the step detecting in a sample from a patient the level or activity of RGS8, a polypeptide comprising RGS8 or a variant thereof, a use of set polypeptide for the diagnosis of a disease, an antibody binding to RGS8, a use of the antibody for the diagnosis of the disease, a method for isolating an autoantibody binding to RGS8, a pharmaceutical composition or medical device comprising the polypeptide according to the present invention, a kit for the diagnosis of a disease comprising the polypeptide or the medical device according to the present invention and a use of the polypeptide, the antibody or the antibody for the manufacture of a kit or medical device.Type: ApplicationFiled: April 16, 2018Publication date: October 25, 2018Inventors: Winfried Stoecker, Lars Komorowski, Ramona Miske, Yvonne Denno, Madeleine Scharf, Christian Probst
-
Publication number: 20180298072Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.Type: ApplicationFiled: June 27, 2018Publication date: October 18, 2018Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stöcker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
-
Publication number: 20160355565Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.Type: ApplicationFiled: June 3, 2016Publication date: December 8, 2016Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Winfried STOECKER, Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Stefanie Hahn, Stephanie Kade, George Trendelenburg
-
Publication number: 20160311876Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.Type: ApplicationFiled: March 23, 2016Publication date: October 27, 2016Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stoecker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
-
Publication number: 20150355177Abstract: The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.Type: ApplicationFiled: June 3, 2015Publication date: December 10, 2015Inventors: Lars KOMOROWSKI, Madeleine SCHARF, Ramona MISKE, Yvonne DENNO, Inga-Madeleine DETTMANN, Christian PROBST, Fedor HEIDENREICH, Ralf GIEß